GlassScriptPhysician profile
Malone L Bales
NPI 1568210292
$1,185.25
in general payments reported to CMS, 2019-2025
13 companies · $744 in 2025
The $744 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $441 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $192.28 | 2024-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $162.38 | 2024-2025 | |
| Biosense Webster, INC. | $140.38 | 2024-2025 | Carto 3 |
| Merck Sharp & Dohme LLC | $135.34 | 2024-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $120.96 | 2024-2025 | Eliquis, Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $111.96 | 2024 | Arcalyst |
| Novo Nordisk INC | $91.37 | 2024-2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.33 | 2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $54.95 | 2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $46.87 | 2024-2025 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.08 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $19.12 | 2025 | |
| Pfizer INC. | $17.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malone Bales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.